Earnings Call Summary | Quoin Pharmaceuticals(QNRX.US) Q4 2023 Earnings Conference
Earnings Call Summary | Quoin Pharmaceuticals(QNRX.US) Q4 2023 Earnings Conference
The following is a summary of the Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript:
Financial Performance:
Quoin Pharmaceuticals Ltd ended the year with around $10.7 million cash and marketable securities, in comparison to $14 million at the end of Q3.
Net loss for the year was reported to be $8.7 million, which is a decrease from the $9.4 million recorded in 2022, mainly due to increase in interest income, lower professional fees, and decreased G&A costs. This was partially offset by the upward trend in R&D spending.
Business Progress:
QNRX has achieved significant progress in clinical trials for Netherton syndrome, receiving the first-ever clinical data from its open IND with the US FDA, providing encouraging and positive results on multiple clinical endpoints.
Quoin successfully submitted several amendments to increase the size of its studies, change the dosing frequency, and reduce eligibility age.
2024 is expected to be a pivotal year for Quoin Pharmaceuticals, as they plan to roll out the first FDA approved treatment for Netherton syndrome.
The company is establishing its own infrastructure to sell their product in the US and Western Europe post approval and has entered into nine commercial partnerships covering 61 entities.
Quoin is also focusing on potential M&A activities as part of their future growth strategy while maintaining a robust balance sheet.
More details: Quoin Pharmaceuticals IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
The following is a summary of the Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript:
以下是Quoin Pharmicals, Ltd.（QNRX）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Quoin Pharmaceuticals Ltd ended the year with around $10.7 million cash and marketable securities, in comparison to $14 million at the end of Q3.
Net loss for the year was reported to be $8.7 million, which is a decrease from the $9.4 million recorded in 2022, mainly due to increase in interest income, lower professional fees, and decreased G&A costs. This was partially offset by the upward trend in R&D spending.
Quoin Pharmicals Ltd在年底擁有約1,070萬美元的現金和有價證券，而第三季度末爲1,400萬美元。
據報道，該年度的淨虧損爲870萬美元，比2022年的940萬美元有所減少，這主要是由於利息收入增加、專業費用降低以及併購成本降低。研發支出的上升趨勢部分抵消了這一點。
Business Progress:
業務進展：
QNRX has achieved significant progress in clinical trials for Netherton syndrome, receiving the first-ever clinical data from its open IND with the US FDA, providing encouraging and positive results on multiple clinical endpoints.
Quoin successfully submitted several amendments to increase the size of its studies, change the dosing frequency, and reduce eligibility age.
2024 is expected to be a pivotal year for Quoin Pharmaceuticals, as they plan to roll out the first FDA approved treatment for Netherton syndrome.
The company is establishing its own infrastructure to sell their product in the US and Western Europe post approval and has entered into nine commercial partnerships covering 61 entities.
Quoin is also focusing on potential M&A activities as part of their future growth strategy while maintaining a robust balance sheet.
QNRX在內瑟頓綜合徵的臨床試驗中取得了重大進展，從其向美國食品藥品管理局開放的IND中獲得了首個臨床數據，在多個臨床終點上提供了令人鼓舞的積極結果。
Quoin成功提交了幾項修正案，以擴大其研究規模，改變給藥頻率並降低合格年齡。
預計2024年將是Quoin Pharmicals的關鍵一年，因爲他們計劃推出第一種經美國食品藥品管理局批准的內瑟頓綜合徵療法。
該公司正在建立自己的基礎設施，以便在獲得批准後在美國和西歐銷售其產品，並已建立了涵蓋61個實體的九個商業合作伙伴關係。
Quoin還將重點放在潛在的併購活動上，這是其未來增長戰略的一部分，同時保持強勁的資產負債表。
More details: Quoin Pharmaceuticals IR
更多詳情： Quoin 製藥投資者
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧